SDK2

Across TCGA pan-cancer cohorts, SDK2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated SDK2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher SDK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SDK2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

KICH, HNSC, and ESCA are the cancer types where SDK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.081	0.904	<.001	30	view →
HNSC	DFS	Median	III,IV	0.207	0.682	.027	21	view →
ESCA	DFS	Median	III,IV	0.023	0.443	<.001	21	view →
BLCA	OS	Median	III,IV	0.175	0.546	.008	15	view →
KIRC	DFS	Median	IV	0.054	0.632	<.001	12	view →
STAD	DFS	Median	III,IV	0.836	0.334	.021	12	view →
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LGG	OS	Median	All	0.195	0.889	<.001	6	view →
PAAD	DFS	Median	All	0.100	0.505	.004	6	view →
LIHC	DFS	Median	III,IV	0.091	0.337	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

SDK2–KICH (DFS)

Open the KICH breakdown →